| HTA in der Praxis | Veröffentlichungen Des Instituts Für Deutsches, Europäisches Und Internationales Medizinrecht, Gesundheitsrecht Und Bioethik Der Universitäten Heidelberg Und Mannheim | 2015 |
| Health Economics of TARGIT | | 2014 |
| Comparative Study of Legal Reasoning in Swiss and UK Courts | | 2014 |
| A Review of Economic Evaluations on New Drugs Priced by Cost Calculation Method in Japan | Japanese Journal of Pharmacoepidemiology/Yakuzai Ekigaku | 2012 |
| Preventing Unnecessary Costs of Drug-Induced Hypoglycemia in Older Adults with Type 2 Diabetes in the United States and Canada | PLoS ONE | 2016 |
| Mapping PedsQL scores onto CHU9D utility scores: estimation, validation and a comparison of alternative instrument versions | Quality of Life Research | 2020 |
| Striving for a Societal Perspective: A Framework for Economic Evaluations When Costs and Effects Fall on Multiple Sectors and Decision Makers | Applied Health Economics and Health Policy | 2019 |
| Critical review and quality-assessment of cost analyses in radiotherapy: How reliable are the data? | Radiotherapy and Oncology | 2019 |
| Cost-effectiveness analysis of new generation coronary CT scanners for difficult-to-image patients | European Journal of Health Economics | 2017 |
| Estimating outcomes and cost effectiveness using a single-arm clinical trial: ofatumumab for double-refractory chronic lymphocytic leukemia | Cost Effectiveness and Resource Allocation | 2017 |
| Treatment cost and life expectancy of diffuse large B-cell lymphoma (DLBCL): a discrete event simulation model on a UK population-based observational cohort | European Journal of Health Economics | 2017 |
| Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community | Pharmacoeconomics | 2016 |
| Comparing Drug and Nondrug Technologies in Comparative Effectiveness Research | | 2016 |
| Endoscopic polypectomy in the clinic: a pilot cost-effectiveness analysis | Clinical Otolaryngology | 2016 |
| Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer | Pharmacoeconomics | 2015 |
| Design of Economic Evaluations of Mindfulness-Based Interventions: Ten Methodological Questions of Which to Be Mindful | Mindfulness | 2015 |
| Output correlations in probabilistic models with multiple alternatives | European Journal of Health Economics | 2015 |
| Comparing Drug and Non-drug Technologies in Comparative Effectiveness Research | | 2015 |
| Introduction to the Technical Issues of Economic Evaluation | | 2015 |
| Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis | Journal of Thrombosis and Thrombolysis | 2015 |
| Cost-effectiveness of the endoscopic versus microscopic approach for pituitary adenoma resection | Laryngoscope | 2015 |
| Cost-Effectiveness and Cost-Utility Analysis of Spinal Cord Stimulation in Patients With Failed Back Surgery Syndrome: Results From the PRECISE Study | Neuromodulation | 2015 |
| Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo | Gastric Cancer | 2015 |
| Making a case for high-volume robotic surgery centers: A cost-effectiveness analysis of transoral robotic surgery | Journal of Surgical Oncology | 2015 |
| Prediction of patient-reported outcome measures via multivariate ordered probit models | Journal of the Royal Statistical Society Series A: Statistics in Society | 2015 |
| Is utility-based quality of life associated with overweight in children? Evidence from the UK WAVES randomised controlled study | BMC Pediatrics | 2015 |
| Review of utility values for economic modeling in type 2 diabetes | Value in Health | 2014 |
| Methods for documenting systematic review searches: a discussion of common issues | Research Synthesis Methods | 2014 |
| Long-term medical costs and life expectancy of acute myeloid leukemia: a probabilistic decision model | Value in Health | 2014 |
| Sharing risk between payer and provider by leasing health technologies: an affordable and effective reimbursement strategy for innovative technologies? | Value in Health | 2014 |
| Review of mixed treatment comparisons in published systematic reviews shows marked increase since 2009 | Journal of Clinical Epidemiology | 2014 |
| Is the UK NICE "reference case" influencing the practice of pediatric quality-adjusted life-year measurement within economic evaluations? | Value in Health | 2014 |
| The cost-effectiveness of the Argus II retinal prosthesis in Retinitis Pigmentosa patients | BMC Ophthalmology | 2014 |
| Health-related productivity loss: NICE to recognize soon, good to discuss now | Pharmacoeconomics | 2014 |
| Diminishing marginal disutility of hypoglycaemic events: results from a time trade-off survey in five countries | Quality of Life Research | 2014 |
| Effectiveness and cost-effectiveness of an awareness campaign for colorectal cancer: a mathematical modeling study | Cancer Causes and Control | 2014 |
| Cost-effectiveness of optimizing acute stroke care services for thrombolysis | Stroke | 2014 |
| Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting β-agonists | Applied Health Economics and Health Policy | 2014 |
| Cost and effectiveness of treatment options for childhood obesity | Pediatric Obesity | 2014 |
| Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis | Cancer Treatment Reviews | 2014 |
| The effect of hypoglycemia on health-related quality of life: Canadian results from a multinational time trade-off survey | Canadian Journal of Diabetes | 2014 |
| Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective | Diabetes, Obesity and Metabolism | 2014 |
| Effectiveness and cost-effectiveness of a telehealth intervention to support the management of long-term conditions: study protocol for two linked randomized controlled trials | Trials | 2014 |
| Targeted rehabilitation to improve outcome after total knee replacement (TRIO): study protocol for a randomised controlled trial | Trials | 2014 |
| Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis | Clinical Drug Investigation | 2014 |
| Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: an economic evaluation alongside a randomised controlled trial | Pharmacoeconomics | 2014 |
| Swedish experience-based value sets for EQ-5D health states | Quality of Life Research | 2014 |
| Comparative cost-effectiveness of the HeartWare versus HeartMate II left ventricular assist devices used in the United Kingdom National Health Service bridge-to-transplant program for patients with heart failure | Journal of Heart and Lung Transplantation | 2014 |
| Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death | Health and Quality of Life Outcomes | 2014 |
| Evaluation of pharmacist care for patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis | International Journal of Clinical Pharmacy | 2014 |
| Cost effectiveness of renal denervation therapy for the treatment of resistant hypertension in the UK | Applied Health Economics and Health Policy | 2014 |
| Modelling outcomes of complex treatment strategies following a clinical guideline for treatment decisions in patients with rheumatoid arthritis | Pharmacoeconomics | 2014 |
| Long-term utility outcomes in patients undergoing endoscopic sinus surgery | Laryngoscope | 2014 |
| Decision making by NICE: examining the influences of evidence, process and context | Health Economics, Policy and Law | 2014 |
| Is utility-based quality of life in children aged 6-7 years affected by Body Mass Index (BMI)? | International Journal of Obesity | 2014 |
| What is the quality of economic evaluations of non-drug therapies? A systematic review and critical appraisal of economic evaluations of radiotherapy for cancer | Applied Health Economics and Health Policy | 2014 |
| Cost-Effectiveness Analysis of Celecoxib in the Treatment of Patients with Chronic Pain in Japan | Iryo To Shakai | 2014 |
| Comparison of an adjustable anchored single-incision mini-sling, Ajust(®) , with a standard mid-urethral sling, TVT-O(TM) : a health economic evaluation | BJU International | 2013 |
| Immunotherapy for Hymenoptera venom allergy: too expensive for European health care? | Allergy: European Journal of Allergy and Clinical Immunology | 2013 |
| Economic analysis of the health impacts of housing improvement studies: a systematic review | Journal of Epidemiology and Community Health | 2013 |
| A Scottish cost analysis of interceptive orthodontics for thumb sucking habits | Journal of Orthodontics | 2013 |
| Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain | Health Economics (United Kingdom) | 2013 |
| Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia | European Journal of Health Economics | 2013 |
| A cost-effectiveness analysis of infrainguinal bypass in the absence of great saphenous vein conduit | Journal of Vascular Surgery | 2013 |
| Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival models | Value in Health | 2013 |
| Reviewing the evidence to inform the population of cost-effectiveness models within health technology assessments | Value in Health | 2013 |
| Cost-Effectiveness Analysis of Aripiprazole Augmentation Treatment of Patients with Major Depressive Disorder Compared to Olanzapine and Quetiapine Augmentation in Turkey: A Microsimulation Approach | Value in Health Regional Issues | 2013 |
| Societal Preferences for EQ-5D Health States from a Brazilian Population Survey | Value in Health Regional Issues | 2013 |
| Measuring preference-based quality of life in children aged 6-7 years: a comparison of the performance of the CHU-9D and EQ-5D-Y--the WAVES pilot study | Quality of Life Research | 2013 |
| Valutazione economica e analisi di budget impact di S-1 (tegafur/gimeracil/oteracil) in pazienti con carcinoma gastrico avanzato | Pharmacoeconomics Italian Research Articles | 2013 |
| Dronedarone per il trattamento della fibrillazione atriale | Pharmacoeconomics Italian Research Articles | 2013 |
| Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE single technology appraisal | Pharmacoeconomics | 2013 |
| Health economic evaluation: important principles and methodology | Laryngoscope | 2013 |
| Parental depression and child conduct problems: evaluation of parental service use and associated costs after attending the Incredible Years Basic Parenting Programme | BMC Health Services Research | 2013 |
| The humanistic and economic burden of systemic lupus erythematosus : a systematic review | Pharmacoeconomics | 2013 |
| Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales | European Journal of Health Economics | 2013 |
| Constructing indirect utility models: some observations on the principles and practice of mapping to obtain health state utilities | Pharmacoeconomics | 2013 |
| Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease | European Journal of Health Economics | 2013 |
| Public health economics: a systematic review of guidance for the economic evaluation of public health interventions and discussion of key methodological issues | BMC Public Health | 2013 |
| A systematic review of utility values for chemotherapy-related adverse events | Pharmacoeconomics | 2013 |
| Mifamurtide for high-grade, resectable, nonmetastatic osteosarcoma following surgical resection: a cost-effectiveness analysis | Value in Health | 2013 |
| Cost-effectiveness of trabectedin plus pegylated liposomal doxorubicin for the treatment of women with relapsed platinum-sensitive ovarian cancer in the UK: analysis based on the final survival data of the OVA-301 trial | Value in Health | 2013 |
| Association between health-related quality of life and body mass after adjustable gastric banding: a nonlinear approach | Value in Health | 2013 |
| Reflections on market access for personalized medicine: recommendations for Europe | Value in Health | 2013 |
| Melding regulatory, pharmaceutical industry, and U.S. payer perspectives on improving approaches to heterogeneity of treatment effect in research and practice | Value in Health | 2013 |
| A UK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource use | Applied Health Economics and Health Policy | 2013 |
| Modelling cost effectiveness of horse antithymocyte globulin for treating severe aplastic anaemia in Germany | Annals of Hematology | 2013 |
| Cost-utility analysis of deferiprone for the treatment of β-thalassaemia patients with chronic iron overload: a UK perspective | Pharmacoeconomics | 2013 |
| Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal | Pharmacoeconomics | 2013 |
| A tutorial on sensitivity analyses in clinical trials: the what, why, when and how | BMC Medical Research Methodology | 2013 |
| Cost-effectiveness of febuxostat in chronic gout | European Journal of Health Economics | 2014 |
| Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis | Osteoporosis International | 2013 |
| Comparative cost-effectiveness of robot-assisted and standard laparoscopic prostatectomy as alternatives to open radical prostatectomy for treatment of men with localised prostate cancer: a health technology assessment from the perspective of the UK National Health Service | European Urology | 2013 |
| Cost-minimisation analysis versus cost-effectiveness analysis, revisited | Health Economics (United Kingdom) | 2013 |
| Lowering the 'floor' of the SF-6D scoring algorithm using a lottery equivalent method | Health Economics (United Kingdom) | 2012 |
| Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder | Pharmacoepidemiology and Drug Safety | 2012 |
| Does the EQ-5D reflect lost earnings? | Pharmacoeconomics | 2012 |
| Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal | Pharmacoeconomics | 2012 |
| Cost-effectiveness analysis of therapies for chronic kidney disease patients on dialysis: a case for excluding dialysis costs | Pharmacoeconomics | 2012 |
| Mechanism-based approach to the economic evaluation of pharmaceuticals: pharmacokinetic/pharmacodynamic/pharmacoeconomic analysis of rituximab for follicular lymphoma | Pharmacoeconomics | 2012 |
